/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/hem---myeloma/,

/clinical/cckm-tools/content/beacon-protocols/hem---myeloma/name-96918-en.cckm

201711332

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Hem - Myeloma

CSC Hem INPT-OP Hyper CVAD - Part (A) Only - Myeloma Ver 10-23-15 (HL3034)

CSC Hem INPT-OP Hyper CVAD - Part (A) Only - Myeloma Ver 10-23-15 (HL3034) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Hem - Myeloma


CSC HEM INPT/OP HYPER CVAD - PART (A) ONLY - MYELOMA VER: 10-23-15 –  Properties
Cycle 1 - HyperCVAD - Myeloma –  11/28/2017 through 12/18/2017 (21 days), Planned
Day 1-5 Inpatient, Cycle 1 - HyperCVAD - Myeloma –  Planned for 11/28/2017
Treatment Plan Information
Reference Information (1)
MULTIPLE MYELOMA: Meletios D., et al. Am J Hematol 1996; 52:77-81
Treatment Plan Summary
DISEASE: Multiple Myeloma; THERAPY (Part A): cyclophosphamide 300 mg/m2 IV every 12 hours times 6 doses Day 1
through 3, mesna 600 mg/m2/DAY administered as a continuous infusion IV over 72 hours on Day 1 through 3. (Total
dose = 1800 mg/m2 IV over 72 hours) (optional); doxorubicin 50 mg/m² IV continuous infusion over 24 hours Day 3
(starting 2 hours after completion of last cyclophosphamide infusion), *If ejection fraction <50%: doxorubicin 25mg/m2
IV continuous infusion over 24 hours Day 1 and 2 (Total dose over 48 hours = Doxorubicin 50mg/m2)*, vinCRIStine 2
mg IV Day 4 and 11, dexamethasone 40 mg PO Day 1 through 4 and Day 11 through 14, (Schedule varies from
reference), GROWTH FACTOR REQUIRED; CYCLE LENGTH: 21 days; COURSE: 2 - 6 cycles.
Dose Modifications
Vincristine - if total bilirubin more than 2mg/dL, reduce to 1mg. Eliminate for total bilirubin greater than 3mg/dL or for
grades 3-4 peripheral neuropathy or ileus.      
Doxorubicin - if total bilirubin is 2-3mg/dL, reduce by 50%; if total bilirubin is 3-4mg/dL, reduce by 75%; if total bilirubin
is greater than 5mg/dL, eliminate.
Consent
Verify Consent
Verify informed consent has been obtained.
Nursing Procedure, Assessment and Monitoring
Measure Intake And Output
EVERY 4 HOURS Starting when released for 5 days
Notify MD if urine output is less than 400mL in 4 hours.
Hydration
sodium chloride 0.9 % infusion
at 100 mL/hr, Intravenous, CONTINUOUS Starting when released Until Discontinued
Begin prior to start of chemotherapy and continue throughout and for 12 hours after the last dose of
cyclophosphamide infusion.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, EVERY 24 HOURS, 4 doses Starting when released
Day 1-4: First dose prior to start of chemotherapy.  May give IV if unable to tolerate PO. If doxorubicin is given over 48
hours, give Day 1-4 .
ondansetron (ZOFRAN) 16 mg in sodium chloride 0.9 % 50 mL bag
16 mg, Intravenous, EVERY 24 HOURS PRN, For 120 hours Starting when released, nausea/vomiting
Day 1-4: First dose prior to start of chemotherapy. May give IV if unable to tolerate PO. If doxorubicin is given over 48
hours, give Day 1-4.
Treatment Medications
dexamethasone (DECADRON) tab 40 mg
40 mg, Oral, EVERY 24 HOURS, 4 doses Starting when released
Day 1-4: Administer prior to chemotherapy.
cyclophosphamide (CYTOXAN) 300 mg/m2 in sodium chloride 0.9 % 250 mL bag
300 mg/m2, Intravenous, EVERY 12 HOURS, 6 doses Starting when released
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
11/28/2017 12:22:15 PM Page 1 of 7
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

doxorubicin CONVENTIONAL (ADRIAMYCIN) 50 mg/m2 in sodium chloride 0.9 % 500 mL infusion
50 mg/m2, Intravenous, ONCE, 1 dose Starting S+2 at 0000
Day 3: Administer after completion of last dose of cyclophosphamide.
If total bilirubin is 2-3mg/dL, reduce doxorubicin dose by 50%; if total bilirubin is 3-4mg/dL, reduce by 75%; if total
bilirubin is greater than 5mg/dL, eliminate.
If Ejection Fraction less than 50% give doxorubicin 25 mg/m2/day in sodium chloride 500 mL continuous infusion over
24 hours for 2 days (Total dose = 50 mg/m2 over 48 hours).
vinCRIStine (ONCOVIN) 2 mg in sodium chloride 0.9 % 25 mL bag
2 mg, Intravenous, ONCE, 1 dose Starting S+3 at 0000, Administer over 3-5 Minutes
Day 4: MUST be administered via gravity through a peripheral IV (not on an infusion pump). If total bilirubin more than
2mg/dL, reduce to 1mg. Eliminate for total bilirubin greater than 3mg/dL or for grades 3-4 peripheral neuropathy or
ileus.
Treatment Medications (delete all that do not apply)
mesna in sodium chloride 0.9% (MESNEX) 20 MG/ML injection 600 mg/m2 (Treatment Plan)
600 mg/m2, Intravenous, EVERY 24 HOURS, 3 doses Starting when released, Administer over 24 Hours
Day 1-3:  Administer over 24 hours. Start one hour prior to start of cyclophosphamide. Total dose = 1800 mg/m2 over
72 hours.
acyclovir (ZOVIRAX) tab 400 mg
400 mg, Oral, 2 X DAILY Starting S As Scheduled
fluconazole (DIFLUCAN) tab 400 mg
400 mg, Oral, 1 X DAILY Starting when released
sulfamethoxazole-trimethoprim (BACTRIM DS) 800-160 MG per tab 1 tab
1 tab, Oral, 2 X DAILY SAT, SUN Include Now
famotidine (PEPCID) tab 20 mg
20 mg, Oral, 1 X DAILY Starting when released
senna-docusate (SENOKOT S) 8.6-50 MG per tab 2 tab
2 tab, Oral, 1 X DAILY Starting S As Scheduled
Hold for loose stools
Conditional Orders
prochlorperazine (COMPAZINE) injection 10 mg
10 mg, Intravenous, EVERY 6 HOURS PRN Starting when released Until Discontinued, nausea/vomiting
IV push slowly, max rate 5 mg/minute.
prochlorperazine (COMPAZINE) tab 10 mg
10 mg, Oral, EVERY 6 HOURS PRN Starting when released Until Discontinued, nausea
ondansetron (ZOFRAN) tab 8 mg
8 mg, Oral, EVERY 8 HOURS PRN Starting when released Until Discontinued, nausea/vomiting
ondansetron (ZOFRAN) 8 mg in sodium chloride 0.9 % 50 mL bag
8 mg, Intravenous, EVERY 8 HOURS PRN Starting when released Until Discontinued, nausea/vomiting
Take Home Medications
dexamethasone (DECADRON) 4 MG tab
Take 10 tabs by mouth one time daily. Take on Day 11 through 14., 40 mg, Disp-40 tab, R-0, 1 X DAILY starting S, Local
Printer
sulfamethoxazole-trimethoprim (BACTRIM DS) 800-160 MG per tab
Take 1 tab by mouth 2 times daily Sat,Sun., 1 tab, Disp-16 tab, R-5, 2 X DAILY SAT, SUN starting S, Local Printer
Take Home Medications (delete all that do not apply)
levofloxacin (LEVAQUIN) 500 MG tab
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
11/28/2017 12:22:15 PM Page 2 of 7
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

Take 1 tab by mouth one time daily. Begin on Day ***, 500 mg, Disp-10 tab, R-0, 1 X DAILY starting
S
TBO-filgrastim (GRANIX) 300 MCG/0.5ML soln prefilled syringe
Inject 300 mcg under skin one time daily in evening. Begin Day ***. Continue until ANC is greater than *** after
nadir., 300 mcg, Disp-10 Syringe, R-5, 1 X DAILY (PM) starting S, Local Printer
RPh may substitute filgrastim at an equivalent dose and qty based on insurance coverage.
TBO-filgrastim (GRANIX) 480 MCG/0.8ML soln prefilled syringe
Inject 480 mcg under skin one time daily in evening. Begin Day ***. Continue until ANC is greater than *** after
nadir., 480 mcg, Disp-10 Syringe, R-5, 1 X DAILY (PM) starting S, Local Printer
RPh may substitute filgrastim at an equivalent dose and qty based on insurance coverage.
Follow-Up
MULTIPLE DAY FOLLOW-UP (1)
LABS: (obtain twice weekly until count recovery): CBC with DIFF.
MULTIPLE DAY FOLLOW-UP (2)
LABS: (obtain weekly until count recovery): Electrolytes, Glucose, BUN, Creatinine, Calcium.
DAY 11 FOLLOW-UP
CHEMOTHERAPY ROOM APPOINTMENT: vinCRIStine for 30 minutes.
DAY 22 FOLLOW-UP
(Day 1 of next cycle): Admit to B6/6 per MD orders.
Day 11 Outpatient, Cycle 1 - HyperCVAD - Myeloma –  Planned for 12/8/2017
Treatment Plan Information
Reference Information (1)
MULTIPLE MYELOMA: Meletios D., et al. Am J Hematol 1996; 52:77-81
Treatment Plan Summary
DISEASE: Multiple Myeloma; THERAPY (Part A): cyclophosphamide 300 mg/m2 IV every 12 hours times 6 doses Day 1
through 3, mesna 600 mg/m2/DAY administered as a continuous infusion IV over 72 hours on Day 1 through 3. (Total
dose = 1800 mg/m2 IV over 72 hours) (optional); doxorubicin 50 mg/m² IV continuous infusion over 24 hours Day 3
(starting 2 hours after completion of last cyclophosphamide infusion), *If ejection fraction <50%: doxorubicin 25mg/m2
IV continuous infusion over 24 hours Day 1 and 2 (Total dose over 48 hours = Doxorubicin 50mg/m2)*, vinCRIStine 2
mg IV Day 4 and 11, dexamethasone 40 mg PO Day 1 through 4 and Day 11 through 14, (Schedule varies from
reference), GROWTH FACTOR REQUIRED; CYCLE LENGTH: 21 days; COURSE: 2 - 6 cycles.
Dose Modifications
Vincristine - if total bilirubin more than 2mg/dL, reduce to 1mg. Eliminate for total bilirubin greater than 3mg/dL or for
grades 3-4 peripheral neuropathy or ileus.      
Doxorubicin - if total bilirubin is 2-3mg/dL, reduce by 50%; if total bilirubin is 3-4mg/dL, reduce by 75%; if total bilirubin
is greater than 5mg/dL, eliminate.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Treatment Conditions
Verify Medication(s) Taken at Home (1)
This medication will not be e-prescribed. If patient is present, script will go to printer.
Otherwise, script will go to nursing or tech pool.   Invalid items: Pharmacy   
Details...
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
11/28/2017 12:22:15 PM Page 3 of 7
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

Verify that patient has taken dexamethasone and document in a progress note.  Notify authorizing prescriber if patient
has not taken medication as prescribed.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Pre-Medications
dexamethasone (DECADRON) tab 40 mg
40 mg, Oral, ONCE, 1 dose Starting when released
Patient's own supply. Take 30 to 60 minutes prior to chemotherapy
Treatment Medications
vinCRIStine (ONCOVIN) 2 mg in sodium chloride 0.9 % 25 mL bag
2 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 3-5 Minutes
MUST be administered via gravity through a peripheral IV (not on an infusion pump). If total bilirubin more than
2mg/dL, reduce to 1mg. Eliminate for total bilirubin greater than 3mg/dL or for grades 3-4 peripheral neuropathy or
ileus.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Cycle 2 - HyperCVAD - Myeloma –  12/19/2017 through 1/8/2018 (21 days), Planned
Day 1-5 Inpatient, Cycle 2 - HyperCVAD - Myeloma –  Planned for 12/19/2017
Treatment Plan Information
Reference Information (1)
MULTIPLE MYELOMA: Meletios D., et al. Am J Hematol 1996; 52:77-81
Treatment Plan Summary
DISEASE: Multiple Myeloma; THERAPY (Part A): cyclophosphamide 300 mg/m2 IV every 12 hours times 6 doses Day 1
through 3, mesna 600 mg/m2/DAY administered as a continuous infusion IV over 72 hours on Day 1 through 3. (Total
dose = 1800 mg/m2 IV over 72 hours) (optional); doxorubicin 50 mg/m² IV continuous infusion over 24 hours Day 3
(starting 2 hours after completion of last cyclophosphamide infusion), *If ejection fraction <50%: doxorubicin 25mg/m2
IV continuous infusion over 24 hours Day 1 and 2 (Total dose over 48 hours = Doxorubicin 50mg/m2)*, vinCRIStine 2
mg IV Day 4 and 11, dexamethasone 40 mg PO Day 1 through 4 and Day 11 through 14, (Schedule varies from
reference), GROWTH FACTOR REQUIRED; CYCLE LENGTH: 21 days; COURSE: 2 - 6 cycles.
Dose Modifications
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
11/28/2017 12:22:15 PM Page 4 of 7
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

Vincristine - if total bilirubin more than 2mg/dL, reduce to 1mg. Eliminate for total bilirubin greater than 3mg/dL or for
grades 3-4 peripheral neuropathy or ileus.      
Doxorubicin - if total bilirubin is 2-3mg/dL, reduce by 50%; if total bilirubin is 3-4mg/dL, reduce by 75%; if total bilirubin
is greater than 5mg/dL, eliminate.
Consent
Verify Consent
Verify informed consent has been obtained.
Nursing Procedure, Assessment and Monitoring
Measure Intake And Output
EVERY 4 HOURS Starting when released for 5 days
Notify MD if urine output is less than 400mL in 4 hours.
Hydration
sodium chloride 0.9 % infusion
at 100 mL/hr, Intravenous, CONTINUOUS Starting when released Until Discontinued
Begin prior to start of chemotherapy and continue throughout and for 12 hours after the last dose of
cyclophosphamide infusion.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, EVERY 24 HOURS, 4 doses Starting when released
Day 1-4: First dose prior to start of chemotherapy.  May give IV if unable to tolerate PO. If doxorubicin is given over 48
hours, give Day 1-4 .
ondansetron (ZOFRAN) 16 mg in sodium chloride 0.9 % 50 mL bag
16 mg, Intravenous, EVERY 24 HOURS PRN, For 120 hours Starting when released, nausea/vomiting
Day 1-4: First dose prior to start of chemotherapy. May give IV if unable to tolerate PO. If doxorubicin is given over 48
hours, give Day 1-4.
Treatment Medications
dexamethasone (DECADRON) tab 40 mg
40 mg, Oral, EVERY 24 HOURS, 4 doses Starting when released
Day 1-4: Administer prior to chemotherapy.
cyclophosphamide (CYTOXAN) 300 mg/m2 in sodium chloride 0.9 % 250 mL bag
300 mg/m2, Intravenous, EVERY 12 HOURS, 6 doses Starting when released
doxorubicin CONVENTIONAL (ADRIAMYCIN) 50 mg/m2 in sodium chloride 0.9 % 500 mL infusion
50 mg/m2, Intravenous, ONCE, 1 dose Starting S+2 at 0000
Day 3: Administer after completion of last dose of cyclophosphamide.
If total bilirubin is 2-3mg/dL, reduce doxorubicin dose by 50%; if total bilirubin is 3-4mg/dL, reduce by 75%; if total
bilirubin is greater than 5mg/dL, eliminate.
If Ejection Fraction less than 50% give doxorubicin 25 mg/m2/day in sodium chloride 500 mL continuous infusion over
24 hours for 2 days (Total dose = 50 mg/m2 over 48 hours).
vinCRIStine (ONCOVIN) 2 mg in sodium chloride 0.9 % 25 mL bag
2 mg, Intravenous, ONCE, 1 dose Starting S+3 at 0000, Administer over 3-5 Minutes
Day 4: MUST be administered via gravity through a peripheral IV (not on an infusion pump). If total bilirubin more than
2mg/dL, reduce to 1mg. Eliminate for total bilirubin greater than 3mg/dL or for grades 3-4 peripheral neuropathy or
ileus.
Treatment Medications (delete all that do not apply)
mesna in sodium chloride 0.9% (MESNEX) 20 MG/ML injection 600 mg/m2 (Treatment Plan)
600 mg/m2, Intravenous, EVERY 24 HOURS, 3 doses Starting when released, Administer over 24 Hours
Day 1-3:  Administer over 24 hours. Start one hour prior to start of cyclophosphamide. Total dose = 1800 mg/m2 over
72 hours.
acyclovir (ZOVIRAX) tab 400 mg
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
11/28/2017 12:22:15 PM Page 5 of 7
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

400 mg, Oral, 2 X DAILY Starting S As Scheduled
fluconazole (DIFLUCAN) tab 400 mg
400 mg, Oral, 1 X DAILY Starting when released
sulfamethoxazole-trimethoprim (BACTRIM DS) 800-160 MG per tab 1 tab
1 tab, Oral, 2 X DAILY SAT, SUN Include Now
famotidine (PEPCID) tab 20 mg
20 mg, Oral, 1 X DAILY Starting when released
senna-docusate (SENOKOT S) 8.6-50 MG per tab 2 tab
2 tab, Oral, 1 X DAILY Starting S As Scheduled
Hold for loose stools
Conditional Orders
prochlorperazine (COMPAZINE) injection 10 mg
10 mg, Intravenous, EVERY 6 HOURS PRN Starting when released Until Discontinued, nausea/vomiting
IV push slowly, max rate 5 mg/minute.
prochlorperazine (COMPAZINE) tab 10 mg
10 mg, Oral, EVERY 6 HOURS PRN Starting when released Until Discontinued, nausea
ondansetron (ZOFRAN) tab 8 mg
8 mg, Oral, EVERY 8 HOURS PRN Starting when released Until Discontinued, nausea/vomiting
ondansetron (ZOFRAN) 8 mg in sodium chloride 0.9 % 50 mL bag
8 mg, Intravenous, EVERY 8 HOURS PRN Starting when released Until Discontinued, nausea/vomiting
Take Home Medications (delete all that do not apply)
levofloxacin (LEVAQUIN) 500 MG tab
Take 1 tab by mouth one time daily. Begin on Day ***, 500 mg, Disp-10 tab, R-0, 1 X DAILY starting S
Follow-Up
MULTIPLE DAY FOLLOW-UP (1)
LABS: (obtain twice weekly until count recovery): CBC with DIFF.
MULTIPLE DAY FOLLOW-UP (2)
LABS: (obtain weekly until count recovery): Electrolytes, Glucose, BUN, Creatinine, Calcium.
DAY 11 FOLLOW-UP
CHEMOTHERAPY ROOM APPOINTMENT: vinCRIStine for 30 minutes.
DAY 22 FOLLOW-UP
(Day 1 of next cycle): Admit to B6/6 per MD orders.
Day 11 Outpatient, Cycle 2 - HyperCVAD - Myeloma –  Planned for 12/29/2017
Treatment Plan Information
Reference Information (1)
MULTIPLE MYELOMA: Meletios D., et al. Am J Hematol 1996; 52:77-81
Treatment Plan Summary
DISEASE: Multiple Myeloma; THERAPY (Part A): cyclophosphamide 300 mg/m2 IV every 12 hours times 6 doses Day 1
through 3, mesna 600 mg/m2/DAY administered as a continuous infusion IV over 72 hours on Day 1 through 3. (Total
This medication will not be e-prescribed. If patient is present, script will go to printer. Otherwise,
script will go to nursing or tech pool.   Invalid items: Pharmacy   Details...
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
11/28/2017 12:22:15 PM Page 6 of 7
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

dose = 1800 mg/m2 IV over 72 hours) (optional); doxorubicin 50 mg/m² IV continuous infusion over 24 hours Day 3
(starting 2 hours after completion of last cyclophosphamide infusion), *If ejection fraction <50%: doxorubicin 25mg/m2
IV continuous infusion over 24 hours Day 1 and 2 (Total dose over 48 hours = Doxorubicin 50mg/m2)*, vinCRIStine 2
mg IV Day 4 and 11, dexamethasone 40 mg PO Day 1 through 4 and Day 11 through 14, (Schedule varies from
reference), GROWTH FACTOR REQUIRED; CYCLE LENGTH: 21 days; COURSE: 2 - 6 cycles.
Dose Modifications
Vincristine - if total bilirubin more than 2mg/dL, reduce to 1mg. Eliminate for total bilirubin greater than 3mg/dL or for
grades 3-4 peripheral neuropathy or ileus.      
Doxorubicin - if total bilirubin is 2-3mg/dL, reduce by 50%; if total bilirubin is 3-4mg/dL, reduce by 75%; if total bilirubin
is greater than 5mg/dL, eliminate.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Pre-Medications
dexamethasone (DECADRON) tab 40 mg
40 mg, Oral, ONCE, 1 dose Starting when released
Patient's own supply. Take 30 to 60 minutes prior to chemotherapy
Treatment Medications
vinCRIStine (ONCOVIN) 2 mg in sodium chloride 0.9 % 25 mL bag
2 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 3-5 Minutes
MUST be administered via gravity through a peripheral IV (not on an infusion pump). If total bilirubin more than
2mg/dL, reduce to 1mg. Eliminate for total bilirubin greater than 3mg/dL or for grades 3-4 peripheral neuropathy or
ileus.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
11/28/2017 12:22:15 PM Page 7 of 7
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org